You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
Axogen, Inc. said it will move forward with a prostate market launch, citing a $754m TAM and Avance® data in >220 reconstructed patients, including ~80% with better than expected erectile function and >95% with return of continence at 6 months.
Axogen reported third-quarter 2026 revenue of $75.8 million, up 26.2%, adjusted EBITDA $13.4 million, and raised full-year revenue guidance to at least $290 million. It completed BioCircuit acquisition October 1st and plans prostate market development 2027.
Axogen reported third-quarter revenue of $75,834, up 26.2%, and net income of $2,334, but nine-month net loss reached $18,766. Cash and investments totaled $348,068 as of September 30, 2026, and Axogen completed the BioCircuit acquisition on October 1, 2026.
Axogen reported third-quarter revenue of $75.8 million, up 26.2%, adjusted net income of $13.1 million and raised full-year guidance to at least $290 million, including at least $7 million from the BioCircuit acquisition completed October 1, 2026.
Axogen completed its acquisition of BioCircuit Technologies. BioCircuit is expected to contribute approximately $6 million in fourth-quarter 2026 and approximately $34 million in 2027 revenue, not included in Axogen’s full-year 2026 guidance of at least 24% revenue growth.
